Stoke Therapeutics (STOK) said Tuesday it has reached alignment with global regulatory agencies on the design of its phase 3 trial of zorevunersen to treat Dravet syndrome.
The company said it has finalized the trial protocol after interactions with the US Food and Drug Administration, the EU's European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency.
The primary endpoint of the study will be a decrease in major motor seizure frequency, the company said, adding key secondary endpoints will include improvements in cognition and behavior. It plans to start the trial in mid-2025.
Stoke also said that zorevunersen has recently obtained US FDA's breakthrough therapy designation.
The company's shares were falling past 13% in recent trading.
Price: 9.52, Change: -1.50, Percent Change: -13.61
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。